$1.08 Billion is the total value of Sofinnova Investments, Inc.'s 150 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | New | Alexion Pharmaceuticals Inc | $27,592,000 | – | 307,300 | +100.0% | 2.55% | – |
| ALGN | New | Align Technology Inc | $8,089,000 | – | 46,500 | +100.0% | 0.75% | – |
| New | Gilead Sciences Inccall | $7,476,000 | – | 100,000 | +100.0% | 0.69% | – | |
| New | Kala Pharmaceuticals Incput | $6,480,000 | – | 737,300 | +100.0% | 0.60% | – | |
| MIRM | New | Mirum Pharmaceuticals Inc | $5,860,000 | – | 418,589 | +100.0% | 0.54% | – |
| PBYI | New | Puma Biotechnology Inc | $5,385,000 | – | 638,026 | +100.0% | 0.50% | – |
| New | Iovance Biotherapeutics Inccall | $4,491,000 | – | 150,000 | +100.0% | 0.42% | – | |
| AXSM | New | Axsome Therapeutics Inc | $4,304,000 | – | 73,163 | +100.0% | 0.40% | – |
| ABBV | New | Abbvie Inc | $3,810,000 | – | 50,000 | +100.0% | 0.35% | – |
| BPMC | New | Blueprint Medicines Corp | $3,690,000 | – | 63,100 | +100.0% | 0.34% | – |
| AGTC | New | Applied Genetic Technologies Corp | $3,485,000 | – | 1,062,615 | +100.0% | 0.32% | – |
| New | Akero Therapeutics Incput | $3,180,000 | – | 150,000 | +100.0% | 0.29% | – | |
| AKRO | New | Akero Therapeutics Inc | $3,146,000 | – | 148,415 | +100.0% | 0.29% | – |
| RIGL | New | Rigel Pharmaceuticals Inc | $2,257,000 | – | 1,446,318 | +100.0% | 0.21% | – |
| New | PTC Therapeutics Inccall | $2,230,000 | – | 50,000 | +100.0% | 0.21% | – | |
| CGEN | New | Compugen Ltd | $2,178,000 | – | 300,000 | +100.0% | 0.20% | – |
| SAGE | New | SAGE Therapeutics Inc | $2,138,000 | – | 74,430 | +100.0% | 0.20% | – |
| MNLO | New | Menlo Therapeutics Inc | $1,621,000 | – | 604,829 | +100.0% | 0.15% | – |
| MRSN | New | Mersana Therapeutics Inc | $1,312,000 | – | 225,000 | +100.0% | 0.12% | – |
| ZGNX | New | Zogenix Inc | $816,000 | – | 32,983 | +100.0% | 0.08% | – |
| ITCI | New | Intra-Cellular Therapies Inc | $800,000 | – | 52,005 | +100.0% | 0.07% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 26 | Q2 2024 | 20.5% |
| Ascendis Pharma A/S | 26 | Q2 2024 | 27.9% |
| NuCana plc | 25 | Q1 2024 | 15.2% |
| Y-mAbs Therapeutics, Inc. | 24 | Q2 2024 | 6.5% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q2 2024 | 2.3% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| PDS Biotechnology Corporation | 22 | Q2 2024 | 0.1% |
| Nucana PLC | 21 | Q1 2024 | 9.7% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nextcure, Inc | 20 | Q2 2024 | 10.8% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-28 |
| 13F-HR/A | 2024-08-15 |
| 13F-HR/A | 2024-08-14 |
| 13F-HR | 2024-08-09 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.